Alamar Biosciences Reports Second Quarter 2026 Financial Results and Provides 2026 Revenue Guidance
Alamar Biosciences reported Q2 2026 revenue of $29.4 million, an 82% increase year-over-year, fueled by a 147% surge in consumable revenue to $15.5 million. Management raised full-year 2026 revenue guidance to $116 million to $120 million, representing 59% growth at the midpoint, supported by the recent launches of the eMTBR-tau and Immune 340 panels.
Key figures
- Revenue
- $29.4 million
- Guidance
- Full year 2026 revenue $116 million to $120 million
- Revenue Yoy
- 82%
- Net loss
- $13.2 million
- Gross margin
- 60%
- Cash position
- $256.3 million
- Operating loss
- $13.5 million
- Consumable revenue
- $15.5 million
- Instrument revenue
- $7.8 million
- Consumable revenue growth
- 147%
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.